Anti-Rheumatic Drugs - India

India

India is projected to experience significant growth in the Anti-Rheumatic Drugs market.
By 2024, the revenue in this market is expected to reach €243.90m in India.
Looking ahead, there is optimism as the market is projected to show an annual growth rate of 1.63% between 2024 and 2029.
This growth trajectory will result in a market volume of €264.50m by 2029 in India.
In terms of global comparison, it is noteworthy that United States is expected to generate the highest revenue in the Anti-Rheumatic Drugs market, with a projected revenue of €32,180.00m in 2024.
India is experiencing a surge in demand for anti-rheumatic drugs due to the high prevalence of rheumatic diseases in the country.

Key regions: Germany, United States, India, Japan, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for Anti-Rheumatic Drugs in India has been growing steadily in recent years.

Customer preferences: Indian customers prefer Anti-Rheumatic Drugs that are affordable and have minimal side effects. They also prefer drugs that are easy to consume and have a long shelf life. Additionally, Indian customers prefer drugs that are manufactured by trusted pharmaceutical companies.

Trends in the market: The Indian Anti-Rheumatic Drugs market has been growing due to an increase in the prevalence of rheumatoid arthritis in the country. The market has also been growing due to an increase in the geriatric population, which is more prone to rheumatoid arthritis. Additionally, the Indian government has been taking steps to improve healthcare infrastructure in the country, which has led to an increase in the availability of Anti-Rheumatic Drugs. The market has also been growing due to an increase in the number of pharmaceutical companies in the country.

Local special circumstances: India has a large population of people suffering from rheumatoid arthritis. The disease is more prevalent in women than in men. Additionally, the disease is more prevalent in urban areas than in rural areas. This is due to lifestyle factors such as lack of exercise and unhealthy diets.

Underlying macroeconomic factors: India has a large pharmaceutical industry that is growing rapidly. The industry is supported by a large pool of skilled workers and a favorable regulatory environment. Additionally, the Indian government has been taking steps to promote the growth of the pharmaceutical industry in the country. The industry is also benefiting from an increase in healthcare spending in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.